Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction

Abstract

Introduction:

In patients with severe sepsis, low levels of activated protein C are associated with high morbidity and mortality. In an observational study we investigated whether patients with cardiogenic shock have decreased circulatory levels of activated protein C, and if these are associated with increased mortality.

Methods:

We measured serum activated protein C and interleukin-6 levels in 43 patients with cardiogenic shock following acute myocardial infarction and in 15 control patients with uncomplicated myocardial infarction at days 0–5 and 7 after the onset of shock/myocardial infarction.

Results:

Activated protein C levels were significantly lower in patients with cardiogenic shock compared to controls. In cardiogenic shock patients, there was no difference in activated protein C levels at baseline, whereas activated protein C levels significantly declined in 28-day non-survivors at day 2, compared with 28-day survivors. Lower levels of activated protein C were associated with a higher degree of vasopressor need, whereas there was no significant association with multiple organ failure in the first days. Regarding the inflammatory response, a strong inverse correlation was observed between interleukin-6 and activated protein C levels.

Conclusion:

Patients with cardiogenic shock who did not survive up to 28 days showed a decline in activated protein C levels during the course of the disease, which was inversely correlated with interleukin-6. This study underlines sustained inflammatory mechanisms in the development and persistence of cardiogenic shock, highlighting a potential effect of anti-inflammatory interventions early during cardiogenic shock.

Keywords

Cardiogenic shock activated protein C acute myocardial infarction

Get full access to this article

View all access options for this article.

References

Bone

Balk

Cerra

. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine, 1992. Chest 2009; 136: e28.

Hochman

. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107: 2998–3002.

Geppert

Steiner

Zorn

. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002; 30: 1987–1994.

Geppert

Dorninger

Delle-Karth

. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006; 34: 2035–2042.

Kohsaka

Menon

Lowe

. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165: 1643–1650.

Griffin

Fernandez

Gale

. Activated protein C. J Thromb Haemost 2007; 5 (Suppl 1): 73–80.

Esmon

. The protein C pathway. Chest 2003; 124: 26S–32S.

Bernard

Vincent

Laterre

. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709.

Sheth

Carvalho

. Protein S and C alterations in acutely ill patients. Am J Hematol 1991; 36: 14–19.

10.

Yan

Helterbrand

Hartman

. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001; 120: 915–922.

11.

Vincent

Moreno

Takala

. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intens Care Med 1996; 22: 707–710.

12.

Geppert

Steiner

Delle-Karth

. Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intens Care Med 2003; 29: 1384–1389.

13.

Jarai

Fellner

Haoula

. Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med 2009; 37: 1837–1844.

14.

Ranieri

Thompson

Barie

. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055–2064.

15.

Niccoli

Biasucci

Biscione

. Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. Atherosclerosis 2008; 196: 779–785.

16.

Toussaint

Gerlach

. Activated protein C for sepsis. N Engl J Med 2009; 361: 2646–2652.

17.

Fourrier

Chopin

Goudemand

. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816–823.

18.

Lorente

Garcia-Frade

Landin

. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536–1542.

19.

Chiba

Nagao

Mukoyama

. Decreased activated protein C levels as a clinical predictor in patients with ST-elevation myocardial infarction. Am Heart J 2008; 156: 931–938.

20.

Laterre

. Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care 2007; 11 (Suppl 5): S5.

21.

Mosnier

Zlokovic

Griffin

. The cytoprotective protein C pathway. Blood 2007; 109: 3161–3172.

22.

Hoffmann

Vollmar

Laschke

. Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. Crit Care 2005; 9 (Suppl 4): S33–S37.

23.

Sennoun

Meziani

Dessebe

. Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 2009; 37: 246–255.

24.

Kerschen

Fernandez

Cooley

. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439–2448.

25.

Borgel

Bornstain

Reitsma

. A comparative study of the protein C pathway in septic and nonseptic patients with organ failure. Am J Respir Crit Care Med 2007; 176: 878–885.

26.

Katz

Stebbins

Alexander

. Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. Am Heart J 2009; 158: 680–687.

27.

Alexander

Reynolds

Stebbins

. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA: the journal of the American Medical Association 2007; 297: 1657–1666.

28.

Prondzinsky

Lemm

Swyter

. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010; 38: 152–160.

29.

Freeman

Natanson

. Anti-inflammatory therapies in sepsis and septic shock. Exp Opin Invest Drugs 2000; 9: 1651–1663.

30.

APEX AMI Investigators; Armstrong

Granger

. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA: the journal of the American Medical Association 2007; 297: 43–51.